Company Information

  

Address: 200 BARR HARBOR DRIVE, SUITE 400  
City: WEST CONSHOHOCKEN 
State: PA 
Zip Code: 19428 
Telephone: 404-380-9263 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. Our lead product candidate, MGL-3196, is a proprietary, liver-directed, selective thyroid hormone receptor-ß, or THR-ß, agonist that can potentially be used to treat a number of disease states with high unmet medical need. THR-ß is known to regulate cholesterol and triglyceride metabolism, which we believe suggests potential therapeutic benefits for patients suffering from hypercholesterolemia, genetic dyslipidemias and diseases resulting from accumulation of fat in liver tissue, such as non-alcoholic steatohepatitis, or NASH.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-0.90NAN/E
03/20174.15NA3.71
12/2016-5.07NAN/E
06/2016-318.52NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.24Total Liab/Total Assets0.12
Net Inc/Total Assets-0.64Total Liab/Inv Cap0.13
Net Inc/Inv Cap-0.72Total Liab/Comm Equity0.04
Pretax Inc/Net SalesNAInterest Coverage Ratio-20.76
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio8.59
Inventory TurnoverNACurrent Ratio8.59
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.96 1.62 1.70 2.23
Operating Income -8.64 -8.44 -6.08 -7.76
Interest Exp 0.00 0.00 0.00 -0.00
Pretax Income -8.36 -8.35 -6.00 -7.75
Other Income 0.27 0.09 0.08 0.01
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -8.36 -8.35 -6.00 -7.75

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 62.14 67.17 40.13 40.50
Receivables - Total NA NA NA 0.00
Inventories - Total NA NA NA NA
Total Current Assets 62.72 67.95 40.35 41.21
Net Property, Plant & Equipment 0.11 0.12 0.01 0.00
Total Assets 62.83 68.07 40.36 41.21
Liabilities        
Accounts Payable 8.52 6.44 5.91 4.80
Debt in Current Liabilities NA NA NA 0.00
Total Current Liabilities 8.52 6.44 5.91 4.80
Long-Term Debt NA NA NA NA
Total Liabilities 8.52 6.44 5.91 4.80
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -98.02 -89.65 -81.31 -75.31
Treasury Stock NA NA NA NA
Total Stockholders' Equity 54.31 61.63 34.45 36.41
Total Liabilities and Stockholders' Equity 62.83 68.07 40.36 41.21

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -4.95 -7.65 -3.77 -5.28
Net Cash Provided by Investing Activities -16.89 -0.65 -10.56 10.08
Net Cash Provided by Financing Activities 0.00 34.88 3.40 5.95

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.15-62.79--
12/20130.00-90.19--
12/20140.00-86.16--
12/20150.00-6.84--
12/20160.00-26.39-5.07
Growth Rates-100.00----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17572,68621.50




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.